InsiderSignal.AI

InsiderSignal.ai

IMRX - Immuneering Corp

Insider Purchase by Schall Thomas J. (Dir)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Schall Thomas J., serving as Dir at Immuneering Corp (IMRX), purchased 21,645 shares at $4.67 per share, for a total transaction value of $101,041.00. Following this transaction, Schall Thomas J. now holds 74,530 shares of IMRX.

This purchase represents a 41.00% increase in Schall Thomas J.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, January 15, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, January 20, 2026, 5 days after the trade was made.

Immuneering Corp operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Schall Thomas J.

Dir

Thomas J. Schall, Ph.D. (age 65) is the Chairman of the Board of Directors at Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company, having joined the board in March 2024 and been appointed Chairman on September 16, 2025.[[3]](https://fintool.com/app/research/companies/IMRX/people/thomas-j-schall)[[4]](https://www.globenewswire.com/news-release/2025/09/16/3150655/0/en/Immuneering-Appoints-Dr-Thomas-Schall-as-Chairman-of-the-Board.html) He is an independent Class I director serving through the 2028 annual meeting, and a member of the Compensation Committee.[[3]](https://fintool.com/app/research/companies/IMRX/people/thomas-j-schall) On January 15, 2026, Schall purchased 21,645 shares of IMRX Class A common stock at an average price of $4.6681 per share, increasing his direct holdings to 74,530 shares.[[1]](https://www.marketbeat.com/instant-alerts/insider-buying-immuneering-nasdaqimrx-director-purchases-21645-shares-of-stock-2026-01-20/)[[5]](https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-fdc0634a4248.html)[[6]](https://www.investing.com/news/insider-trading-news/immuneering-director-schall-buys-101k-in-shares-93CH-4455522) Schall founded ChemoCentryx, Inc. in 1997 and served as its President, CEO, and Chairman for 25 years until its $4 billion acquisition by Amgen in 2022, during which he led the FDA approval of Tavneos® for ANCA-associated vasculitis.[[3]](https://fintool.com/app/research/companies/IMRX/people/thomas-j-schall)[[4]](https://www.globenewswire.com/news-release/2025/09/16/3150655/0/en/Immuneering-Appoints-Dr-Thomas-Schall-as-Chairman-of-the-Board.html) His earlier career includes scientist roles at DNAX Research Institute (Schering-Plough) from 1993–1997 and Genentech prior to 1993, contributing to chemokine receptor discoveries.[[3]](https://fintool.com/app/research/companies/IMRX/people/thomas-j-schall) He holds a B.S. in Biology from Northern Illinois University and a Ph.D. in Cancer Biology from Stanford University.[[3]](https://fintool.com/app/research/companies/IMRX/people/thomas-j-schall)

View full insider profile →

Trade Price

$4.67

Quantity

21,645

Total Value

$101,041.00

Shares Owned

74,530

Trade Date

Thursday, January 15, 2026

37 days ago

SEC Filing Date

Tuesday, January 20, 2026

Filed 5 days after trade

HEALTHCAREBIOTECHNOLOGY

About Immuneering Corp

Company Overview

No company information available
View news mentioning IMRX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3266999

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime